Lyophilized Antivenins Market is Segmented By Type(Neurotoxin, Blood Toxin, Mixed Toxin), By Application (Hospitals, Medical Centers, Ambulatory Surgical Centers, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030
The "lyophilized antivenins market" size is estimated to reach at a high CAGR during the forecast period 2023-2030
Antivenom is a specialized treatment for envenomation known as antivenin, venom antiserum, and antivenom immunoglobulin. A major worry about the efficiency of snakebites treatment in tropical locations is the failure of liquid antivenom (AV) delivery due to a lack of a suitable cold chain in remote areas. Freeze-drying has been recommended to reduce this problem and increase AV stability.
Lyophilized Antivenins Market Scope
|
Metrics |
Details |
|
Market CAGR |
High |
|
Segments Covered |
By Type, By Application, and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
Market Dynamics
The increasing incidence of snakebites and lack of adequate cold chain facilities in remote regions is estimated to drive the lyophilized antivenins market.
Increasing incidence of snakebites is estimated to drive the lyophilized antivenins market
Snakebites are a severe public health issue in tropical countries, with higher morbidity and death rates in poor, underdeveloped, rural, and inaccessible rainforest settings. Snakebites cause at least 421,000 envenomings and 20,000 deaths worldwide each year, but the number could be as high as 1,841,000 envenomings and 94,000 deaths. A total of 400,000 amputations have been recorded, and other serious health repercussions such as infection, tetanus, scarring, contractures, and psychological consequences. The Brazilian official monitoring system documented 416,109 snakebites, with an average of 26,000 occurrences per year. Snakebites are more common in the Brazilian Amazon states, with 55.4 incidents per 100,000 people in 2015, and are considered an occupational health hazard among rural and riverine populations. However, because only a few countries have an effective system for epidemiological surveillance of these incidents, the true burden of snakebites is likely larger and more difficult to measure. The case mortality rate in the Brazilian Amazon is believed to be 0.6 per cent, and it is linked to older age and delayed medical intervention. Antivenom (AV) immunoglobulins, included in the WHO List of Essential Medicines, are the only treatment available for snakebites envenomings.
Lack of adequate cold chain facilities in remote regions is estimated to drive the lyophilized antivenins market
The inability to deliver widespread and timely liquid AV in the Amazon and other tropical places is a key worry about snakebites treatment effectiveness. Due to a lack of a proper cold chain, AV distribution to health facilities in rural locations is hampered, resulting in delayed patient care and, as a result, greater complications and case fatality rates. In addition, improper storage and transportation can lead to material loss. To mitigate this issue, freeze-drying AV immunoglobulins have been recommended to improve their stability.
This extra step, together with various stabilizers, results in AVs that are more stable than liquid formulations, especially in tropical climates where high temperatures might decrease immunoglobulin function. However, data from clinical trials on the efficacy and safety of freeze-dried AVs is still scarce. Despite its complexity, lyophilization has grown commonplace in various industries, including pharmaceuticals, biotechnology, and agriculture. Lyophilization offers several benefits due to the negative effects of heat and water, ranging from improved sample stability and purity to longer shelf life and lower costs.
Disadvantages associated with antivenom is estimated to hamper the lyophilized antivenins market
Current animal plasma-derived antivenoms have several drawbacks. Early adverse effects occur within 24 hours of antivenom administration. Patients may experience early adverse reactions (within 24 hours) due to de novo complement activation (non-IgE reactions) or as a result of IgE-mediated anaphylactic events after earlier exposure to animal antibodies. Approximately 70% of antivenom antibodies aren't directed against medically important venom toxins. As a result, envenomed patients will be given a higher-than-required dose of equine antibodies, which have no therapeutic utility but may produce side effects. Excessive antivenom antibodies mixed with evoked human anti-horse antibodies (IgGs and IgMs) may result in complex immune overproduction. 1–2 weeks after antivenom medication, these may be deposited in blood vessels, glomeruli, and joints, triggering inflammation and causing serum sickness.
However, access to antivenoms remains a major barrier to general use; antivenoms are still extremely expensive and scarce in high-risk locations. To alleviate the lack of antivenoms where they are most useful rural health centers, health authorities, producers, and distributors of antivenoms and treating physicians and even patients must make a special effort to increase their use and reduce their use morbidity and mortality caused by envenomations. The discussions suggest the intended features of antivenoms as public health tools (efficacy, tolerability, stability, and accessibility, especially economic accessibility) and the challenges that still hamper their usage and recommendations for improving accessibility.
Market Industry Analysis
PEST Analysis:
COVID-19 Impact Analysis
COVID-19 has affected the healthcare industry negatively. To stop its spread, government-imposed lockdown. People are fearful they may experience occupational effects and negative health from the COVID-19 pandemic. All the other treatments and drug approvals were delayed due to the demand for COVID-19 treatment. This has affected the lyophilized antivenins market as many have stopped manufacturing units.
Market Segment Analysis
Neurotoxin’s segment is estimated to dominate the lyophilized antivenins market
Neurotoxins are artificial or naturally occurring compounds that harm, destroy, or disrupt the central and peripheral nervous systems' functioning ability. Neurotoxins can cause loss of nuclei and axonal tracts and demyelination in neurons, axons, and glia. They may also produce metabolic disturbances, which can negatively affect the nervous system (CNS). The capacity of antivenom molecules to bind with toxins in venom determines how effective it is against that venom. This is the ability of the antivenom molecules to bind with the neurotoxins in the venom in terms of neurotoxicity.
The avidity of the antivenom, which is a combined effect of the affinity constants of the different antibodies towards different toxins; the relative abundance of antibodies in the antivenom against the individual neurotoxins; and the relative abundance of the individual neurotoxins in the snake venom of interest are all factors that influence. The ability of antivenom to prevent or reverse the effects of venom in a clinical environment might be characterised by its effectiveness. In terms of neurotoxicity, antivenom effectiveness is defined as the ability of antivenom to prevent or reverse neurotoxicity in snakebite patients.
The hospital segment is estimated to dominate the lyophilized antivenins market
Antivenoms are the only medicines that can be used to treat snakebite envenomings. These products are solely for use in hospitals and should be given as quickly as possible to stop the venom's effects. Antivenoms are particular for one or more types of venoms that need to be neutralised; hence they must be used in the areas where these snakes are located. The availability of lyophilized antiveins and more facilities available in hospitals is estimated to dominate the market.
For example, CoRal-ICP antivenom of hospital use, specific to treat envenoming from bites by most coral snakes in Central and North America.
Lyophilized Antivenins Market Geographical Analysis
North America region is estimated to dominate the lyophilized antivenins market
According to CDC, In the United States, an estimated 7,000–8,000 people are bitten by venomous snakes each year, with around 5 dying. In 2021, The US Food and Drug Administration (FDA) has approved a new expanded indication for ANAVIP® (Crotalidae immune F(ab')2 (equine), an equine-derived antivenin, for the management of Neurotoxinand paediatric patients with North American Pit Viper envenomation, according to Rare Disease Therapeutics, Inc. (RDT). Rattlesnake, Copperhead, and Cottonmouth/Water Moccasin envenomations are now included in this new enlarged indication. ANAVIP was formerly approved for the treatment of Neurotoxinand paediatric rattlesnake envenomation in North America. In collaboration with Laboratorios Silanes, S.A. de C.V., RDT only markets ANAVIP in the United States.
Market Competitive Landscape
The major key players in the lyophilized antivenins market are Vins Bioproducts Limited, Premium Serums, Merck, Quirupos, Cedimed, Servicio de Comercio Internacional, NEWGPC Imports, ETP Life Sciences S.A., Serum Biotech and DroguerĂa e Importacione s Alemana
Merck
Overview: Merck is a leading worldwide biopharmaceutical business that has been developing medicines and vaccines for many of the world's most difficult diseases for more than a century. The company interacts with clients and operates in more than 140 countries to deliver innovative health solutions through prescription medications, vaccines, biological therapies, and animal health products. They also show their dedication to expanding access to health care by implementing far-reaching policies, programmes, and collaborations.
Product Portfolio: The company specializes in Healthcare, Life Science and Electronics.
Key Development: In 2020, Merck, known as MSD outside the United States and Canada, acquired Pandion Therapeutics, Inc. common stock at a purchase price of $60 per share, made through a subsidiary.
Frequently Asked Questions
What is the Projected CAGR value of the Lyophilized Antivenins Market?
Lyophilized Antivenins Market is expected to grow at a High CAGR during the forecasting period 2023-2030.
Which region controlled the global market during 2023-2030?
North America region Controls the Lyophilized Antivenins Market during 2023-2030.
Which is the fastest growing region in the Lyophilized Antivenins Market?
Among all regions, Asia Pacific is the fastest growing market share during the forecast period.
